2024 Update on the Multimodality Management of Bladder and Kidney Cancer


2024 Update on the Multimodality Management of Bladder and Kidney Cancer Banner



Date & Location
Thursday, November 21, 2024, 12:00 PM - Saturday, November 23, 2024, 1:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

Specialties
Specialties - Anatomic Pathology, Biostatistics, Clinical Pathology, Cytopathology, Epidemiology, General Surgery, Genetic Counseling, Genitourinary Oncology, Hospitalist, Immunotherapy, Industry, Internal Medicine, Molecular Biology, Molecular Pathology, Nuclear Medicine, Nursing, Oncology and Hematology, Pathology, Patient or Caregiver, Physician Assistant, Radiation Oncology, Surgical Oncology, Surgical Pathology, Urology

Overview

This program is designed to highlight the latest developments in the multidisciplinary management of bladder and kidney cancers. The aim of the course is provide attendees with information that will aid in the delivery of state-of-the-art care to patients with all stages of bladder and kidney cancers. Highlights of this year's program include:

— Management strategies for localized kidney cancer and non-muscle invasive bladder cancer
— Neoadjuvant and adjuvant systemic therapies for muscle-invasive bladder cancer
— Treatment paradigms for advanced kidney cancer and optimal surgical approaches for high-risk cases
— Advanced imaging modalities for kidney cancer
— The role of intraoperative and SBRT techniques for treating bladder and kidney cancers
— A review of hereditary kidney cancer syndromes

The keynote presentation will detail the new standards in managing advanced urothelial cancer. Updated trial data will be presented, detailing recent changes in the standard of care for advanced urothelial cancer, focusing on combination therapies that include novel antibody-drug conjugates and checkpoint inhibitors. Additionally, the program will include video sessions that highlight surgical techniques for urinary diversion, utilizing both open and robotic methods, as well as radical nephrectomy with thrombectomy.

Attendees have the option to participate either in person or virtually. This course is intended for urologists, urologic-oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, nurses, and other healthcare professionals.

Objectives
At the conclusion of this program, attendees will be able to:

  1. Present a multidisciplinary approach to the management of bladder and kidney cancer including surgical, medical, and radiation therapies
  2. Disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer
  3. Integrate new therapeutics into the treatment of localized, locally advanced, and metastatic bladder and kidney cancers

Registration

This course offers participants the choice of attending either in person or virtually. In-person registrants will be provided continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Registration Rates

Physicians (MDs, PhDs, and DOs): $600
Advanced Practice Providers: $450
Residents, and Fellows: $400
Nurses and Other Healthcare Providers: $350
Industry Professionals*: $1,050
MSK Employees: Complimentary

For details on our cancellation terms, please review our Cancellation Policy.

*An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.00 credits/points in the following certification programs:

  • Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition Program; and
  • Lifelong Learning (Part II) credits for the American Board of Pathology (ABPath) Continuing Certification program; and
  • Accredited CME and Self-Assessment credits for the American Board of Surgery (ABS) Continuous Certification program; and

MOC/CC points will be reported to your board within 45 days upon completion of the course.

ANCC CNE Statement

Memorial Sloan Kettering Cancer Center–Nursing Professional Development / Continuing Education is accredited with distinction as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation.

13.25 contact hours will be awarded to participants who attend the program in its entirety and complete a program evaluation. Partial credit not awarded.